Beta Drugs Ltd Share Price & Stock Analysis

Beta Drugs Ltd (NSE: BETA) is a Panchkula, Haryana-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹1,897 Cr, it ranks #1,272 by market cap among the 6,197 Indian listed companies on FinBizNet, and #39 of 86 in Medicinal Chemicals and Botanical Products. At ₹1,811.20 (as of 16 Nov 2026), the share price is 35.5% below its 52-week high of ₹2,807.90 and 82.9% above its 52-week low of ₹990.10. The share price is up 8.8% over one year and down 30.0% over three months.

Key Metrics

Current Price₹1,811.20
Market Cap₹1,897 Cr
NSE SymbolBETA
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals
Sub-IndustryBiotechnology and Life Sciences > Medicinal Chemicals and Botanical Products
P/E Ratio44.9
Return on Equity18.77%
Return on Assets7.85%
52-Week Range₹990.10 – ₹2,807.90
1-Year Price Change+8.8%
3-Month Price Change-30.0%
Beta (1Y)0.1
HeadquartersPanchkula, Haryana
Websitebetadrugslimited.com

Latest Quarterly Results — Q2 FY27

Revenue₹137 Cr
Net Profit₹19 Cr
Net Margin14.0%
EPS (Basic)₹16.59
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Beta Drugs Ltd Quarterly Revenue and Profit Trend

Beta Drugs Ltd reported revenue of ₹137 Cr in Q2 FY27, up 9.5% from ₹126 Cr in Q1 FY27. It posted a net profit of ₹19 Cr for the quarter, against a net profit of ₹16 Cr in Q1 FY27 (up 16.9%). Across the 4 quarters from Q3 FY26 to Q2 FY27, quarterly revenue ranged from ₹87 Cr (Q3 FY26) to ₹137 Cr (Q2 FY27). The company was profitable in each of these 4 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹137 Cr₹19 Cr14.0%
Q1 FY27₹126 Cr₹16 Cr13.1%
Q4 FY26₹94 Cr₹9 Cr9.6%
Q3 FY26₹87 Cr₹9 Cr9.8%

Consolidated figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 58.91% of Beta Drugs Ltd's shares as of Sept 2026, against 64.90% in Dec 2025 (−5.99 percentage points). Delivery averaged 44.6% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About Beta Drugs Ltd

Beta Drugs Limited develops, manufactures, and sells anti-cancer bulk drugs and finished dosages in India. The company offers cosmeceutical and oncology products. It also manufactures active pharmaceutical ingredients (API) and pharmaceutical formulation intermediates (PFI). The company exports its products. Beta Drugs Limited was founded in 1985 and is based in Panchkula, India.

Products and Services

1. Manufacturing of Oncology Medicines-This segment develops, manufactures, and trades in oncology medicines.

Business Segments

1. Trading and Manufacturing of Pharmaceutical Products-100%

Beta Drugs Ltd vs Peers — Medicinal Chemicals and Botanical Products

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Sun Pharmaceutical Industries Limited₹4,56,425 Cr39.514.72%₹16,199 Cr+11.2%
Laurus Labs Ltd₹1,31,242 Cr145.617.74%₹2,206 Cr+146.8%
Zydus Lifesciences Ltd₹1,19,651 Cr24.118.32%₹7,910 Cr+26.0%
Dr.Reddys Lab₹1,15,464 Cr26.911.52%₹8,698 Cr+14.5%
Cipla Limited₹1,14,712 Cr29.311.74%₹7,404 Cr-7.6%
Mankind Pharma₹1,09,870 Cr5712.45%₹4,338 Cr+16.7%
Aurobindo Pharma Ltd.₹1,05,150 Cr309.93%₹10,263 Cr+59.8%
Lupin Ltd₹92,087 Cr17.326.91%₹7,827 Cr+0.4%
Beta Drugs Ltd₹1,897 Cr44.918.77%₹137 Cr+8.8%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Beta Drugs Ltd?

Beta Drugs Ltd is trading at ₹1,811.20, with a market capitalisation of ₹1,897 Cr.

Which sector does Beta Drugs Ltd belong to?

Beta Drugs Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).

What are the key financial ratios of Beta Drugs Ltd?

Beta Drugs Ltd has a P/E of 44.9 and a return on equity of 18.77%.

What is the stock symbol of Beta Drugs Ltd?

Beta Drugs Ltd is listed on the NSE under the symbol BETA.

How has Beta Drugs Ltd's share price moved over the past year?

Beta Drugs Ltd's share price is up 8.8% over one year and down 30.0% over three months. Its 52-week range is ₹990.10 to ₹2,807.90.

What were Beta Drugs Ltd's latest quarterly results?

In Q2 FY27, Beta Drugs Ltd reported revenue of ₹137 Cr and net profit of ₹19 Cr, with basic EPS of ₹16.59 (consolidated, parsed from the company's exchange filing).

What is the promoter holding in Beta Drugs Ltd?

Promoters held 58.91% of Beta Drugs Ltd's shares as of Sept 2026, against 64.90% in Dec 2025 (−5.99 percentage points).

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.